SCHEMBL25845885

SCHEMBL25845885

CCCCOC(=O)C1CCN(c2ccc(NC3CCC(=O)NC3=O)cc2)CC1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 14/20 0.57
DDB1 Q16531 11/20 0.57
MAPT P10636 4/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
TP53 P04637 1/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44
KMT2A Q03164 1/20 0.44
RELA Q04206 1/20 0.44
HDAC3 O15379 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
ALDH1A1 P00352 2/20 0.40
HIF1A Q16665 1/20 0.40
HSP90AA1 P07900 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30376308 0.87 CRBN (0.57) CRBNDDB1MAPTNPC1RAB9A
SCHEMBL23783394 0.83 DDB1 (0.57) CRBNDDB1MAPTALDH1A1
SCHEMBL29942803 0.83 CRBN (0.52) CRBNDDB1MAPTNPC1RAB9A
SCHEMBL30066424 0.82 CRBN (0.50) CRBNDDB1KMT2AALDH1A1HSP90AA1
SCHEMBL30965700 0.81 CRBN (0.50) CRBNDDB1MAPTNPC1RAB9A
SCHEMBL30965612 0.81 CRBN (0.48) CRBNDDB1MAPTNPC1RAB9A
SCHEMBL31333782 0.81 CRBN (0.44) CRBNDDB1HDAC3HDAC1HDAC2
SCHEMBL23783204 0.81 DDB1 (0.70) CRBNDDB1
SCHEMBL30965572 0.79 CRBN (0.48) CRBNDDB1MAPTNPC1RAB9A
SCHEMBL30376716 0.78 CRBN (0.54) CRBNDDB1HDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691972-B2 Compounds for targeted degradation of BRD9 C4 THERAPEUTICS, INC. (US) 2023-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691972-B2 Compounds for targeted degradation of BRD9 BRD9, BRD1, BRWD1 CRBN 188/4885DDB1 390/4885MAPT 1277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.